Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Flutemetamol f-18 - Generic Drug Details

« Back to Dashboard

What are the generic drug sources, and freedom to operate, for flutemetamol f-18?

Flutemetamol f-18 is the generic ingredient in one branded drug marketed by Ge Healthcare and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has sixty-six patent family members in twenty-three countries.

One supplier is listed for this compound.

Summary for Generic Name: flutemetamol f-18

Tradenames:1
Patents:6
Applicants:1
NDAs:1
Drug Master File Entries: 0
Suppliers / Packagers: see list1
Bulk Api Vendors: see list1
Clinical Trials: see list11
Patent Applications: see list11
Drug Prices:see low prices
DailyMed Link:flutemetamol f-18 at DailyMed

Pharmacology for Ingredient: flutemetamol f-18

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes7,351,401► SubscribeYY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes8,691,185► Subscribe ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes8,236,282► SubscribeYY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes8,691,185► Subscribe ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes8,916,131► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: flutemetamol f-18

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,911,707Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
9,134,328Methods of using benzothiazole derivative compounds and compositions► Subscribe
8,404,213Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
7,854,920Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: flutemetamol f-18

Country Document Number Estimated Expiration
Spain2536449► Subscribe
Portugal1334091► Subscribe
Norway2015006► Subscribe
Norway2015005► Subscribe
Russian Federation2324686► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FLUTEMETAMOL F-18

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0006France► SubscribePRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
00724Netherlands► SubscribePRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
3 5003-2015Slovakia► SubscribePRODUCT NAME: FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
2015001Lithuania► SubscribePRODUCT NAME: FLUTEMETAMOLUM (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
15/004Ireland► SubscribePRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc